The ALS Association and workplace learning company Schoox are partnering to offer education resources to providers, ...

Verge Genomics will use digital biomarkers to assess short-term disease progression in an ALS trial testing its VRG50635 ...

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

TRE-515, a small molecule inhibitor of deoxycytidine kinase, is being developed for autoimmune diseases and in clinical ...

Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...

Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied ...

SNUG01 is a first-in-class targeted gene therapy that’s designed to increase the levels of TRIM72, a protein with ...

Neurosense reports Canadian regulators want a meeting that could lead to PrimeC's conditional approval there, and further ...

Columnist Kristin Neva says a couple days in the Florida sunshine, away from the demands of caregiving, did wonders for her ...

The U.S. Food and Drug Administration approved treatment for 11 patients with the rare familial ALS caused by mutations in ...

Improvement may seem unlikely for people with ALS, but columnist Dagmar Munn shares how she's learned to set health goals — ...